Japan’s Takeda and Biological E. Ltd. have agreed to collaborate on affordable combination vaccines.
Takeda will transfer its measles and acellular pertussis vaccine bulk production technology to BE under license, the firms said on Monday. It would also provide support for production and quality control and technical assistance in pre-clinical study design and production of clinical and first commercial batches.
BE gets the rights to use Takeda’s measles and pertussis vaccine technologies for combinations such as MR vaccine as well as any pertussis-containing combination, and will be solely responsible for conducting and funding the development activities.
BE will commercialise the vaccines in markets including India and China..
The tie-up gives BE an opportunity to diversify its geographic reach, Managing Director Mahima Datla said. “We look forward to contributing to the measles elimination goals and protection against rubella.”
